Remarkable response to Rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia
The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who c...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
[2001]
|
| In: |
Leukemia and lymphoma
Year: 2001, Volume: 42, Issue: 3, Pages: 551-553 |
| ISSN: | 1029-2403 |
| DOI: | 10.3109/10428190109064616 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3109/10428190109064616
|
| Author Notes: | G. Egerer, K. Sauerland & A.D. Ho (Department of Internal Medicine V, Hematology, Oncology and Rheumatology, Universityof Heidelberg) |
| Summary: | The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who cannot tolerate chemotherapy because of marrow aplasia. We observed a continuous complete remission induced by rituximab alone in a 72 year old patients with refractory and progressive high-grade non-Hodgkin's lymphoma (NHL) in the phase of chemotherapy induced marrow aplasia. |
|---|---|
| Item Description: | Elektronische Reproduktion der Druckausgabe Gesehen am 21.12.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1029-2403 |
| DOI: | 10.3109/10428190109064616 |